4/A: MiNK Therapeutics CEO Amends Stock Ownership Filing
Amendment to Beneficial Ownership Statement
MiNK Therapeutics CEO Jennifer Buell filed an amended Form 4 to correct previously reported stock transactions related to tax withholdings.
Summary
- An amendment to a Form 4 filing was submitted by Jennifer Buell, Chief Executive Officer of MiNK Therapeutics, Inc. (INKT).
- The amendment corrects an error in the original Form 4 filed on September 11, 2025.
- It reports the disposition of 5,351 shares of common stock on September 9, 2025, at a price of $15.36 per share.
- These shares were withheld for the payment of withholding taxes in relation to stock issued to Jennifer Buell.
- Following this reported transaction, Jennifer Buell beneficially owns 36,492 shares of common stock directly.
Sentiment
Score: 5
Explanation: The filing is a routine administrative correction of an executive's beneficial ownership statement, specifically detailing shares withheld for tax purposes. It provides no new material information regarding the company's operational performance, financial health, or strategic direction, thus having a neutral impact on sentiment.
Positives
- Increased transparency in executive compensation reporting due to the correction of previously omitted details.
Negatives
- An initial administrative error occurred in the original reporting of executive stock transactions.
Future Outlook
No forward-looking statements or guidance are provided in this administrative filing.
Management Comments
- The amendment corrects an error in the original Form 4, which did not include the shares withheld for payment of withholding taxes in Table I.
Industry Context
This filing is a routine compliance disclosure for an executive's stock transaction and does not contain information related to broader industry trends or competitive landscape.
Related Party Transactions
- Shares were withheld by MiNK Therapeutics, Inc. for payment of withholding taxes related to stock issued to CEO Jennifer Buell on September 9, 2025, which is a standard compensation-related transaction between a company and its executive.
Stakeholder Impact
- Shareholders: Provides clearer and more accurate disclosure of executive stock ownership, enhancing transparency.
Key Dates
| Date | Description |
|---|---|
| 09/09/2025 | Date of earliest transaction (stock issuance and tax withholding) |
| 09/11/2025 | Date of original Form 4 filing |
| 10/03/2025 | Date of amendment filing (signature date) |
Recommendation
holdThe filing is an administrative correction to an executive's beneficial ownership statement, specifically regarding shares withheld for tax purposes. It does not contain any material information about the company's financial performance, operational outlook, or strategic direction that would warrant a change in investment recommendation.
Keywords
MiNK Therapeutics, INKT, Jennifer Buell, CEO, Form 4, SEC filing, stock transaction, beneficial ownership, tax withholding, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.